
Onward Medical N.V (ONWD) | Financial Analysis & Statements
Onward Medical N.V. | Mid-cap | Healthcare
Onward Medical N.V. | Mid-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
76.1M
Total Liabilities
28.1M
Shareholders Equity
48.1M
Debt to Equity
0.58
Cash Flow Metrics
Revenue & Profitability Trend
Onward Medical N.V Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 229.0K | 68.0K | 0 | 0 | 0 |
Cost of Goods Sold | 22.0K | 0 | 14.7M | 12.0M | 2.3M |
Gross Profit | 207.0K | 68.0K | -14.7M | -12.0M | -2.3M |
Gross Margin % | 90.4% | 100.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 12.4M | 13.8M | 13.1M | 7.9M | 5.8M |
Selling, General & Administrative | 5.7M | 6.3M | 6.5M | 7.8M | 3.0M |
Other Operating Expenses | 3.5M | 2.8M | 3.9M | 993.0K | 361.0K |
Total Operating Expenses | 21.6M | 23.0M | 23.5M | 16.7M | 9.2M |
Operating Income | -34.9M | -35.5M | -32.0M | -28.5M | -15.5M |
Operating Margin % | -15,223.6% | -52,151.5% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | 791.0K | 972.0K | 62.0K | 1.0K | 0 |
Interest Expense | 2.0M | 1.4M | 1.5M | 5.6M | 4.4M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -35.8M | -36.1M | -33.5M | -34.2M | -20.0M |
Income Tax | -40.0K | 107.0K | -766.0K | 69.0K | 20.0K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -35.7M | -36.2M | -32.8M | -34.3M | -20.0M |
Net Margin % | -15,600.4% | -53,207.4% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -32.9M | -34.0M | -31.3M | -28.3M | -15.3M |
EPS (Basic) | €-0.80 | €-1.20 | €-1.09 | €-3.62 | €-3.39 |
EPS (Diluted) | €-0.80 | €-1.20 | €-1.09 | €-3.62 | €-3.39 |
Basic Shares Outstanding | 44629000 | 30184000 | 30184000 | 9485000 | 5900000 |
Diluted Shares Outstanding | 44629000 | 30184000 | 30184000 | 9485000 | 5900000 |
Income Statement Trend
Onward Medical N.V Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 60.0M | 29.8M | 41.8M | 89.4M | 6.4M |
Short-term Investments | - | - | 20.0M | - | - |
Accounts Receivable | 160.0K | 0 | - | - | - |
Inventory | 102.0K | 0 | - | - | - |
Other Current Assets | - | 305.0K | 285.0K | 2.2M | 416.0K |
Total Current Assets | 63.6M | 31.4M | 64.2M | 92.4M | 7.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | 0 | 2.2M | 149.0K |
Goodwill | 12.4M | 11.6M | 12.1M | 11.7M | 8.4M |
Intangible Assets | 8.5M | 8.0M | 8.3M | 8.3M | 5.2M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | -1.0K | - | - | - | - |
Total Non-Current Assets | 12.5M | 12.2M | 12.4M | 12.4M | 7.2M |
Total Assets | 76.1M | 43.6M | 76.6M | 104.8M | 14.2M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.3M | 1.4M | 1.9M | 952.0K | 911.0K |
Short-term Debt | 597.0K | 568.0K | 427.0K | 473.0K | 137.0K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 9.3M | 6.7M | 8.2M | 5.5M | 2.7M |
Non-Current Liabilities | |||||
Long-term Debt | 14.5M | 16.3M | 14.0M | 13.2M | 41.9M |
Deferred Tax Liabilities | 303.0K | 631.0K | 670.0K | 2.0M | 1.3M |
Other Non-Current Liabilities | - | - | - | 1.0K | - |
Total Non-Current Liabilities | 18.8M | 19.0M | 15.7M | 16.6M | 43.6M |
Total Liabilities | 28.1M | 25.7M | 24.0M | 22.1M | 46.3M |
Equity | |||||
Common Stock | 5.4M | 3.6M | 3.6M | 3.6M | 0 |
Retained Earnings | -181.8M | -145.4M | -108.3M | -76.0M | -53.1M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 48.1M | 17.9M | 52.6M | 82.7M | -32.1M |
Key Metrics | |||||
Total Debt | 15.1M | 16.9M | 14.4M | 13.7M | 42.0M |
Working Capital | 54.3M | 24.7M | 56.0M | 86.8M | 4.3M |
Balance Sheet Composition
Onward Medical N.V Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -35.8M | -36.1M | -33.5M | -34.2M | -20.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 2.7M | 2.6M | 1.7M | 8.6M | 2.7M |
Working Capital Changes | -1.9M | 491.0K | 140.0K | -2.4M | -221.0K |
Operating Cash Flow | -33.9M | -32.2M | -30.1M | -22.3M | -13.0M |
Investing Activities | |||||
Capital Expenditures | -150.0K | -422.0K | -386.0K | -91.0K | -173.0K |
Acquisitions | - | - | - | - | - |
Investment Purchases | 0 | 0 | -20.0M | 0 | - |
Investment Sales | 0 | 20.0M | 0 | - | - |
Investing Cash Flow | -150.0K | 19.6M | -20.4M | -91.0K | -173.0K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 14.1M | 1.3M | 0 | 30.0M | 3.9M |
Debt Repayment | -15.3M | 0 | - | - | - |
Financing Cash Flow | 68.9M | 1.3M | 0 | 110.1M | 4.5M |
Free Cash Flow | -31.9M | -32.7M | -27.1M | -22.2M | -13.1M |
Net Change in Cash | 34.9M | -11.3M | -50.5M | 87.7M | -8.7M |
Cash Flow Trend
Onward Medical N.V Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-6.48
Forward P/E
-4.65
Price to Book
8.34
Price to Sales
85.17
Profitability Ratios
Profit Margin
90.39%
Operating Margin
-1,685.49%
Return on Equity
-167.80%
Return on Assets
-43.66%
Financial Health
Current Ratio
4.34
Debt to Equity
54.33
Beta
0.95
Per Share Data
EPS (TTM)
€-0.74
Book Value per Share
€0.62
Revenue per Share
€0.06
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
onwd | 245.2M | -6.48 | 8.34 | -167.80% | 90.39% | 54.33 |
Argenx SE | 38.4B | 37.82 | 6.33 | 24.72% | 41.03% | 0.71 |
UCB S.A | 39.1B | 29.72 | 4.00 | 14.30% | 19.45% | 29.72 |
Hyloris | 169.7M | - | 5.24 | -17.81% | -64.98% | 5.65 |
European Medical | 21.8M | 44.15 | 2.35 | 5.40% | 1.14% | 191.98 |
Celyad Oncology S.A | 13.4M | -0.17 | 25.00 | -170.92% | 0.00% | 177.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.